Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative invasive breast cancer classified as low risk by Curebest™ 95GC Breast in a multi‑institutional registry study

• DOI: 10.3892/ol.2023.13794
• Publication Date: 2023-04-05T11:07:17Z
• Authors: Yasuto Naoi; Ryo Tsunashima; Kenzo Shimazu; Masahiro Oikawa; Seiichi Imanishi; Hiroshi Koyama; Yoshihiko Kamada; Kazuhiro Ishihara; Masahiko Suzuki; Tomo Osako; Takayuki Kinoshita; Akihiko Suto; Seigo Nakamura; Hitoshi Tsuda; Shinzaburo Noguchi
• Keywords: HER2 negative

Curebest™ 95GC breast (95GC) is a multigene classifier we developed for the prognostic prediction of patients with estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative and node-negative (ER+/HER2-/n0) invasive cancer treated adjuvant endocrine therapy alone. The aim preset study was to evaluate clinical utility in multiinstitutional registry study. Patients (n=215) ER+/HER2-/n0 who had undergone assay seven hospitals were consecutively recruited at various postoperative times. At recruitment, no disease recurrences prospectively followed up median 62 (range, 6-91) months. Of 124 classified as low risk, 118 received alone six chemo-endocrine therapy. Only two distant recurrences, 5-year recurrence-free survival (DRFS) high 98.0%. 91 81 10 A total four these (5-year DRFS=95.5%). Among high-risk patients, prognosis significantly improved compared 77 (historical controls) (P=0.0002; hazard ratio, 0.24). Compared St. Gallen 2013 guideline, significant de-escalation from 73.1% (155/212) 40.6% (86/212) chemotherapy achieved. excellent risk could be validated present study, indicating that useful safe cancer.